ERBB2 and breast carcinoma: Merkin et al. studied tissues from 164 breast cancer patients, among which 82% (28/34) of triple-negative [estrogen receptor [ER]/progesterone receptor/human epidermal growth factor receptor-2 (HER2) negative] breast cancers showed positive KRT17 expression.